CL2020003373A1 - Composición y método de ahorro de opiáceos - Google Patents

Composición y método de ahorro de opiáceos

Info

Publication number
CL2020003373A1
CL2020003373A1 CL2020003373A CL2020003373A CL2020003373A1 CL 2020003373 A1 CL2020003373 A1 CL 2020003373A1 CL 2020003373 A CL2020003373 A CL 2020003373A CL 2020003373 A CL2020003373 A CL 2020003373A CL 2020003373 A1 CL2020003373 A1 CL 2020003373A1
Authority
CL
Chile
Prior art keywords
opiate
sparing
composition
opioids
relates
Prior art date
Application number
CL2020003373A
Other languages
English (en)
Inventor
Harry Karelis
Original Assignee
Zelira Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zelira Therapeutics Operations Pty Ltd filed Critical Zelira Therapeutics Operations Pty Ltd
Publication of CL2020003373A1 publication Critical patent/CL2020003373A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas que comprenden ?9 -tetrahidrocannabinol (THC), cannabidiol (CBD) y una fracción terpénica obtenida por extracción de una planta de Cannabis, y su uso en el tratamiento de la dependencia y / o adicción a opioides. La invención también se refiere a métodos para ahorrar opioides.
CL2020003373A 2018-07-03 2020-12-23 Composición y método de ahorro de opiáceos CL2020003373A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2018100928A AU2018100928A4 (en) 2018-07-03 2018-07-03 Composition and method for opioid sparing

Publications (1)

Publication Number Publication Date
CL2020003373A1 true CL2020003373A1 (es) 2021-08-13

Family

ID=63079660

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003373A CL2020003373A1 (es) 2018-07-03 2020-12-23 Composición y método de ahorro de opiáceos

Country Status (13)

Country Link
US (1) US20210290592A1 (es)
EP (1) EP3817734A4 (es)
KR (1) KR20210071941A (es)
AU (2) AU2018100928A4 (es)
BR (1) BR112020027070A2 (es)
CA (1) CA3104741A1 (es)
CL (1) CL2020003373A1 (es)
CO (1) CO2021001057A2 (es)
IL (1) IL279903A (es)
MX (1) MX2021000023A (es)
PE (1) PE20211586A1 (es)
SG (1) SG11202013194VA (es)
WO (1) WO2020006598A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3134108A1 (en) * 2019-03-21 2020-09-24 ZYUS Life Sciences US Ltd. Cannabinoid and application supported opioid tapering
AU2021215262B2 (en) * 2020-06-12 2023-12-14 Zelira Therapeutics Operations Pty Ltd Composition and method for treating chronic pain
EP4362936A1 (en) * 2021-07-01 2024-05-08 Ananda Scientififc, Inc. Methods for treatment of pain with cannabinoids
WO2023144340A1 (en) 2022-01-28 2023-08-03 Vertanical GmbH Method for the production of a plant extract
WO2023144420A1 (en) 2022-01-31 2023-08-03 Vertanical GmbH Composition comprising delta-9-tetrahydrocannabinol and terpenes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3209312A1 (en) * 2014-10-21 2017-08-30 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
WO2017054071A1 (en) * 2015-01-21 2017-04-06 Willinsky Michael Composition and methods to improve stability, dosing, pharmacodynamics and product shelf life of endocannabinoids, phytocannabinoids and synthetic cannabinoids delivered by nasal inhaler
AU2018275687A1 (en) * 2017-05-31 2020-01-02 Phytecs, Inc. Pharmaceutical compositions comprising cannabidiol and beta-caryophyllene and methods for their use
CA3080468A1 (en) * 2017-10-30 2019-05-09 Endocanna Health, Inc. Cannabinoid formulations

Also Published As

Publication number Publication date
EP3817734A4 (en) 2022-03-16
KR20210071941A (ko) 2021-06-16
CO2021001057A2 (es) 2021-06-30
IL279903A (en) 2021-03-01
WO2020006598A1 (en) 2020-01-09
AU2019297197A1 (en) 2021-01-28
PE20211586A1 (es) 2021-08-18
CA3104741A1 (en) 2020-01-09
EP3817734A1 (en) 2021-05-12
BR112020027070A2 (pt) 2021-03-30
MX2021000023A (es) 2021-05-27
US20210290592A1 (en) 2021-09-23
AU2018100928A4 (en) 2018-08-09
SG11202013194VA (en) 2021-01-28

Similar Documents

Publication Publication Date Title
CL2020003373A1 (es) Composición y método de ahorro de opiáceos
CL2020003368A1 (es) Composicion y metodo para tratar el dolor
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CO2017004974A2 (es) Extractos de cannabis y métodos de preparación.
PE20200676A1 (es) Composicion de cannabis
AU2016261707A8 (en) Use of cannabis to treat fibromyalgia, methods and compositions thereof
MX2019003735A (es) Formulaciones diluibles de cannabinoides y procesos para su preparacion.
PE20230607A1 (es) Composicion de cannabis
CO2017008437A2 (es) Métodos de purificación de cannabinoides, composiciones y kits de los mismos
MX2019002198A (es) Composiciones solubles en agua que comprenden cannabinoides purificadas.
PE20200726A1 (es) Composicion de cannabis
IN2014DN09507A (es)
CL2019003635A1 (es) Composiciones y tratamientos para el trastorno del sueño.
MX2020001443A (es) Sistema y métodos de extracción fitoquímica para extraer fitoquímicos de plantas incluidas las plantas de la familia cannabaceae sensu stricto.
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
MX2017015083A (es) Composiciones cosmeticas que comprenden e/z-bencilideno-5,6-dimeto xi-3,3-dimetilindan-1-ona.
CL2020003374A1 (es) Composicion y metodo de cannabinoides para tratar el tept y/o la ansiedad
CO2019000787A2 (es) Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
MX2021005474A (es) Plantas con perfil de cannabinoides enriquecido con cannabidiol.
BR112016017612A2 (pt) Uso de um extrato de uma planta do gênero mentha da família lamiaceae
BR112017003581A2 (pt) borracha natural resistente à oxidação e um método para sua produção
CO2021017846A2 (es) Complejos macromoleculares de fungicida de ditiocarbamato
CY1124457T1 (el) Συνθεση για τη θεραπεια του βηχα
CO2019000604A2 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d